Refine by MP, party, committee, province, or result type.
Health committee Very simply, they recommended to Zamboni that he should do things the way they're normally done—that is, go first to a phase one and two trial before moving to a large number of patients, as we always do with clinical trials. It's the normal prudent process. You first demonstrate
March 1st, 2012Committee meeting
Dr. Alain Beaudet
Health committee I am not aware of any precedent. Irrespective of MS now—and I think I've been very clear on this topic, publicly—I think it would be a dangerous precedent to legislate the type and the object of research that we carry out and that the federal government would be supporting in thi
March 1st, 2012Committee meeting
Dr. Alain Beaudet
Health committee There is no doubt that personalized medicine is a major hope for all countries. Progress has been made in research in the U. S. and in Europe. Asia is also beginning to see some advancement. I think that Canada was lagging a bit behind in this area. That is why a major strategy o
March 1st, 2012Committee meeting
Dr. Alain Beaudet
Health committee That's an excellent question, Dr. Carrie. As you know, one of the numerous difficulties, to start with, has been in establishing protocols of research to even demonstrate whether or not there was a higher prevalence of an association of CCSVI with patients with MS than with patie
March 1st, 2012Committee meeting
Dr. Alain Beaudet
Health committee Obviously, I cannot comment on the policy aspects of things, that would be for Health Canada.
March 1st, 2012Committee meeting
Dr. Alain Beaudet
Health committee I'm sure they will be happy to provide you with an answer when they meet with you. What I can tell you, however, is that we have been very sensitive and sensitized to this very important project for many years. You are absolutely right that the nature of these diseases is such
March 1st, 2012Committee meeting
Dr. Alain Beaudet
Health committee We can send you the presentation.
March 1st, 2012Committee meeting
Dr. Alain Beaudet
Health committee Thank you, Madam Chair. I would first like to thank your committee for inviting me to speak to you about research activities dealing with neurological diseases in Canada and to provide you with an update on recent activity related to multiple sclerosis. Today I would like to hi
March 1st, 2012Committee meeting
Dr. Alain Beaudet
Health committee As you know, Canada is extremely successful in the area of neurosciences, mental health, and addiction. Actually we're talking about tobacco. We also have researchers known internationally for their work on the control of tobacco use. Broadly, for the year 2009-10, if I remember
November 21st, 2011Committee meeting
Dr. Alain Beaudet
Health committee As far as I understand it, there is.
November 21st, 2011Committee meeting
Dr. Alain Beaudet
Health committee This is correct. You are very well informed. We will indeed be funding a $1 million endowed chair on autism, most specifically to look at the clinical treatment of autism.
November 21st, 2011Committee meeting
Dr. Alain Beaudet
Health committee Actually there have been several financial allocations. In fact, there's a provision for a roughly $25 million investment from CIHR to be matched by different countries. We're talking about several MOUs. There's one with the U.K. and Germany; there's one with France; there's one
November 21st, 2011Committee meeting
Dr. Alain Beaudet
Health committee The drug safety and effectiveness network has been launched and is very successful. It has several collaborative centres we've set up that collaborate through the country. One of the major successes is that, respectively, they've managed not only to access data banks from the d
November 21st, 2011Committee meeting
Dr. Alain Beaudet
Finance committee In the health sector, specifically?
October 19th, 2011Committee meeting
Dr. Alain Beaudet
Finance committee Universities.
October 19th, 2011Committee meeting
Dr. Alain Beaudet